Inter-modality relationship constrained multi-modality multi-task feature selection for Alzheimer's Disease and mild
Feng Liu1, Chong-Yaw Wee, Huafu Chen
1Key Laboratory for NeuroInformation of Ministry of Education, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China; Image Display, Enhancement, and Analysis (IDEA) Laboratory, Biomedical Research Imaging Center (BRIC) and Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Neuroimage
|September 19, 2013
Summary
This study introduces a new multi-task learning method for Alzheimer's Disease (AD) diagnosis using multi-modal data. The approach enhances accuracy by preserving complementary information between imaging modalities like PET and MRI.
Area of Science:
- Neuroimaging
- Machine Learning
- Biomedical Data Analysis
Background:
- Multi-modal data integration improves Alzheimer's Disease (AD) diagnosis.
- Traditional feature selection methods ignore inter-modality relationships.
- Existing multi-task learning may overlook complementary information across modalities.
Purpose of the Study:
- To propose a novel multi-task feature selection method for AD diagnosis.
- To preserve complementary inter-modality information while performing joint feature selection.
- To enhance classification accuracy by effectively integrating multi-modal data.
Main Methods:
- A novel multi-task feature selection approach is proposed.
- Constraints are imposed to preserve inter-modality relationships and enforce feature sparseness.
- A multi-kernel Support Vector Machine (SVM) integrates selected features for classification.
Main Results:
- Achieved 94.37% accuracy and 0.9724 AUC for AD identification.
- Achieved 78.80% accuracy and 0.8284 AUC for mild cognitive impairment (MCI) identification.
- Achieved 67.83% accuracy and 0.6957 AUC for differentiating MCI converters from non-converters.
Conclusions:
- The proposed method demonstrates superior performance over state-of-the-art classification techniques.
- Effective integration of multi-modal data through novel feature selection improves diagnostic accuracy for AD and MCI.
- The method successfully captures complementary information across imaging modalities for enhanced disease classification.
Keywords:
Alzheimer's DiseaseInter-modality relationshipMild cognitive impairmentMulti-kernel support vector machineMulti-task feature selectionMore Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...